TiGenix The Latest Partner In Takeda Deal Frenzy
This article was originally published in PharmAsia News
The latest in a non-stop succession of deals over the past few weeks for Takeda sees the Japanese major add a late-stage TiGenix asset to its GI care portfolio, with Europe to be the initial focus of the tie-up.
You may also be interested in...
Takeda will acquire its Belgian biotech partner, TiGenix, to strengthen its gastro-intestinal portfolio, bolster its regenerative medicines capacity and grow its US specialty care presence.
J&J’s Janssen Biotech subsidiary won FDA approval for the IL-12/IL-23 inhibitor Stelara to treat Crohn’s disease, giving it a second-line position alongside anti-TNF therapies for patients in need of new options.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.